Sanofi(SNY) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% [4][10] - For the full year 2025, sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates, which is at the upper end of the guidance [11][12] - Business EPS growth was strong at 26.7%, with business EPS excluding share buyback growing by 12.2% [10][12] - Free cash flow returned to strong levels at EUR 8.1 billion, representing 18.5% of sales, with a target to sustainably reach at least 20% in the medium term [12][13] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines grew by 34% in 2025, with full year sales of EUR 1.8 billion for RSV protection [4][10] - Dupixent achieved EUR 4.2 billion in Q4 and EUR 15.7 billion in annual sales, with over 30% increase in patients [5][10] - ALTUVIIIO reached blockbuster status with EUR 1.2 billion in full year sales, and Ayvakit reached $725 million in annual pro forma sales [4][10] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full year sales reaching EUR 7.9 billion [5][6] - Beyfortus grew 9.5% to EUR 1.8 billion, driven by geographic expansion [5][6] - The company expanded its market presence in China, obtaining approvals for several global and China-only medicines [22] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma company, focusing on innovation and strategic acquisitions [3][7] - The completion of the Opella transaction allowed reinvestment into business development and M&A opportunities [3][12] - The company aims to increase its dividend for the 31st consecutive year and has completed a EUR 5 billion share buyback program [15] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver profitable growth close to 2025 levels, with high single-digit growth in sales [15][16] - The company anticipates a slight decline in vaccine sales in 2026 and plans to optimize its portfolio through divestments [16] - Management highlighted the importance of maintaining a strong capital structure and financial flexibility for future growth opportunities [13][15] Other Important Information - The company co-developed PAS 2090, a global standard for measuring and reducing the environmental impact of medicines and vaccines [8] - The company is focused on expanding its pipeline with strategic acquisitions, including Dynavax Technologies Corporation [7][63] Q&A Session Questions and Answers Question: Can you elaborate on the Dupixent rollout since CSU and COPD? - The Dupixent rollout has shown strong performance with 25% growth year-over-year, culminating in a 32% growth in Q4, driven by new indications [29][30] Question: What is the outlook for Beyfortus in 2026? - Beyfortus had a 9% increase in 2025, and while it's early to provide specific guidance for 2026, the company is optimistic about its performance [33][34] Question: Can you provide more detail on the Amlitelimab case related to Kaposi sarcoma? - Kaposi sarcoma is associated with herpes virus, and while there is a theoretical risk with immunomodulators, the benefit-risk profile remains favorable [46][48] Question: What are the prospects for growth and earnings looking forward to 2027? - The company expects a negative impact from the loss of R&D reimbursement from Regeneron, but this will be offset by increased Amvutra royalties [53][54]